cardiovascularКардиоваскулярная терапия и профилактикаCardiovascular Therapy and Prevention1728-88002619-0125«SILICEA-POLIGRAF» LLCcardiovascular-1610Research ArticleОБЗОРЫREVIEWSСтатины и их антиаритмическая активностьStatins and their antiarrhythmic activityЗагидуллинН. Ш.ZagidullinN. Sh.nau36@ufanet.ruMichelsG.MichelsG.nau36@ufanet.ruЗагидуллинШ. З.ZagidullinSh. Z.nau36@ufanet.ruБашкирский государственный медицинский университет, УфаBashkir State Medical University, UfaIII Кельнская университетская клиника, КельнIII Cologne University Clinic, Cologne20070101197068116121Copyright © Загидуллин Н.Ш., Michels G., Загидуллин Ш.З., 19701970Загидуллин Н.Ш., Michels G., Загидуллин Ш.З.Zagidullin N.S., Michels G., Zagidullin S.Z.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://cardiovascular.elpub.ru/jour/article/view/1610

Клинические испытания используемых в настоящее время антиаритмических препаратов нередко свидетельствуют об их неэффективности при развитии жизнеугрожающих желудочковых аритмий и внезапной коронарной смерти (ВКС), а также о недостаточном фармакологическом контроле фибрилляции предсердий (ФП). Статины обладают помимо холестерин-снижающего действия рядом плейотропных эффектов (противовоспалительный, антипролиферативный, улучшение эндотелиальной функции и т.п.). Они способны снизить риск развития жизнеугрожающих аритмий и ВКС у больных острым инфарктом миокарда, перенесших коронарную реваскуляризацию и с наличием имплантированного кардиовертера-дефибриллятора. Терапия статинами способна уменьшить риск возникновения рецидивов ФП.

Clinical trials of modern antiarrhythmics often demonstrate their ineffectiveness in life-threatening ventricular arrhythmias and sudden cardiac death (SCD), as well as inadequate pharmacological control in atrial fibrillation (AF). Together with cholesterol-lowering effect, statins demonstrate various pleiotropic effects (anti-inflammatory, anti-proliferative, endothelial function improvement, etc.). Statins can reduce the risk of life-threatening arrhythmias and SCD in patients with acute myocardial infarction, after coronary revascularization and implantation of cardioverter-defibrillator. Statin therapy may decrease recurrent AF risk.

статиныантиаритмический эффектфибрилляция предсердийвнезапная смертьstatinsantiarrhythmic effectatrial fibrillationsudden deathReferencesZipes DP, Wellens HL. Sudden cardiac death. Circulation 1998; 98: 2334-51.Zipes DP, Wellens HL. Sudden cardiac death. Circulation 1998; 98: 2334-51.Cheung BM, Lauder IJ, Lau CP, Kumana CR. Meta-analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes. Br J Clin Pharmacol 2004; 57: 640-51.Cheung BM, Lauder IJ, Lau CP, Kumana CR. Meta-analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes. Br J Clin Pharmacol 2004; 57: 640-51.Burke AP, Farb A, Malcom GT, et al. Coronary risk factors and plaque morphology in men with coronary artery disease who died suddenly. N Engl J Med 1997; 336: 1276-82.Burke AP, Farb A, Malcom GT, et al. Coronary risk factors and plaque morphology in men with coronary artery disease who died suddenly. N Engl J Med 1997; 336: 1276-82.Nissen SE, Nicholls SJ, Sipahi I, et al. Effect of high-intensive statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006; 295: 1556-65.Nissen SE, Nicholls SJ, Sipahi I, et al. Effect of high-intensive statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006; 295: 1556-65.Ridler PM. High-sensitivity C-reactive protein: potential action for global risk assessment in the primery prevention of cardiovascular disease. Circulation 2001; 103: 1813-8.Ridler PM. High-sensitivity C-reactive protein: potential action for global risk assessment in the primery prevention of cardiovascular disease. Circulation 2001; 103: 1813-8.Dupuis J, Tardif JC, Carnacek P, Theroux P. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial. Circulation 1999; 99: 3227-33.Dupuis J, Tardif JC, Carnacek P, Theroux P. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial. Circulation 1999; 99: 3227-33.Rosenson RS, Taggney CC. Antiatherothrombotic properties of statins: implications for cardiovascular evet reduction. JAMA 1998; 279: 1643-50.Rosenson RS, Taggney CC. Antiatherothrombotic properties of statins: implications for cardiovascular evet reduction. JAMA 1998; 279: 1643-50.Tsiara S, Elisaf M, Mikhalaidis DP. Early vascular benefits of statin therapy. Curr Med Res Opin 2003; 19: 540-56.Tsiara S, Elisaf M, Mikhalaidis DP. Early vascular benefits of statin therapy. Curr Med Res Opin 2003; 19: 540-56.Cascio WE. Myocardial ischemia: what factors determine arrhythmogenesis? J Cardiovasc Electrophysiol 2001; 12: 726-9.Cascio WE. Myocardial ischemia: what factors determine arrhythmogenesis? J Cardiovasc Electrophysiol 2001; 12: 726-9.Pound EM, Kang JX, Leaf A. Partitioning of polyunsaturated fatty acids, which prevent cardiac arrhythmias, into phospholipid cell membranes. J Lipid Res 2001; 42: 346-51.Pound EM, Kang JX, Leaf A. Partitioning of polyunsaturated fatty acids, which prevent cardiac arrhythmias, into phospholipid cell membranes. J Lipid Res 2001; 42: 346-51.Rikitake Y, Kawashima S, Takeshita S, et al. Anti-oxidative properties of fluvastatine, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits. Atherosclerosis 2001; 154: 87-96.Rikitake Y, Kawashima S, Takeshita S, et al. Anti-oxidative properties of fluvastatine, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits. Atherosclerosis 2001; 154: 87-96.Quintara M, Storck N, Lindvall K, Ericson M. Heart rate variability as a means of assessing pronosis after acute myocardial infaction. A 3-year follow-up study. Eur Heart J 1997; 18: 789-97.Quintara M, Storck N, Lindvall K, Ericson M. Heart rate variability as a means of assessing pronosis after acute myocardial infaction. A 3-year follow-up study. Eur Heart J 1997; 18: 789-97.Pehlivanidis AN, Athyros VG, Demitrias DS, et al. Heart rate variability after long-term treatment with atorvastatin in hypercholesterolaemic patients with or without coronary artery disease. Atherosclerosis 2001; 157: 463-9.Pehlivanidis AN, Athyros VG, Demitrias DS, et al. Heart rate variability after long-term treatment with atorvastatin in hypercholesterolaemic patients with or without coronary artery disease. Atherosclerosis 2001; 157: 463-9.Vrotcek B, Okrajcek R, Golicnik A, et al. Atrovastatin Therapy Increases Heart Rate Variability, Decraeses QT Variablility, and shortens QTc Interval Duration in Patients With Advanced Chronic Heart Failure. J Card Fail 2005; 9: 684-90.Vrotcek B, Okrajcek R, Golicnik A, et al. Atrovastatin Therapy Increases Heart Rate Variability, Decraeses QT Variablility, and shortens QTc Interval Duration in Patients With Advanced Chronic Heart Failure. J Card Fail 2005; 9: 684-90.Makijarvi M, Breithhard G, Reinhardt L, et al. Signal averaged electrocardiogram: update 1997. Ann Noninvas Electrocardiol 1997; 2: 384-94.Makijarvi M, Breithhard G, Reinhardt L, et al. Signal averaged electrocardiogram: update 1997. Ann Noninvas Electrocardiol 1997; 2: 384-94.Kayikcioglu M, Can L, Evrengul H, et al. The effect of statin therapy on ventricular late potentials in acute myocardial infarction. Int J Cardiol 2003; 90: 63-72.Kayikcioglu M, Can L, Evrengul H, et al. The effect of statin therapy on ventricular late potentials in acute myocardial infarction. Int J Cardiol 2003; 90: 63-72.Lee TM, Chou TF, Tsai CH. Effects of pravastatin on cardiomyocyte hypertrophy and ventricular vulnerability in normolipidemic rats after myocardial infarction. J Mol Cell Cardiol 2003; 35: 1449-59.Lee TM, Chou TF, Tsai CH. Effects of pravastatin on cardiomyocyte hypertrophy and ventricular vulnerability in normolipidemic rats after myocardial infarction. J Mol Cell Cardiol 2003; 35: 1449-59.Fonarow GC, Wright RS, Spencer FA, et al. National registry of myocardial infarction 4 investigators: effect of statin use within 24 the first 24 hours of admission for acute myocardial infarction on early morbidity and mortality. Am J Cardiol 2005; 26: 611-6.Fonarow GC, Wright RS, Spencer FA, et al. National registry of myocardial infarction 4 investigators: effect of statin use within 24 the first 24 hours of admission for acute myocardial infarction on early morbidity and mortality. Am J Cardiol 2005; 26: 611-6.Donati MI, Elnicki DM, Jain AC, Gibson CM. Effect of preoperative statin therapy and cardiac outcomes after coronary bypass grafting. Am J Cardiol 2000; 86(10): 1128-30.Donati MI, Elnicki DM, Jain AC, Gibson CM. Effect of preoperative statin therapy and cardiac outcomes after coronary bypass grafting. Am J Cardiol 2000; 86(10): 1128-30.Pan W, Pintar T, Anton J, et al. Statins are associated with a reduced incidence of perioperative mortality after coronary artery bypass graft surgery. Circulation 2004; 110: II45-9.Pan W, Pintar T, Anton J, et al. Statins are associated with a reduced incidence of perioperative mortality after coronary artery bypass graft surgery. Circulation 2004; 110: II45-9.Mitchell LB, Powel JL, Gillis AM, et al. AVID investigators: are lipid-lowering drugs also antiarrhythmic drugs? An analysis of the Antiarrhythmics versus Implantable Defibrillators (AVID) trial. JACC 2003; 42: 81-7.Mitchell LB, Powel JL, Gillis AM, et al. AVID investigators: are lipid-lowering drugs also antiarrhythmic drugs? An analysis of the Antiarrhythmics versus Implantable Defibrillators (AVID) trial. JACC 2003; 42: 81-7.Vyas AK, Guo H, Moss AJ, et al. Reduction in ventricular tachyarrhythmias with statins in the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II. JACC 2006; 47: 769-73.Vyas AK, Guo H, Moss AJ, et al. Reduction in ventricular tachyarrhythmias with statins in the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II. JACC 2006; 47: 769-73.De Suttere J, Tavernier R, De Buyzere M, et al. Lipid-lowering drugs and recurrences of life-treating ventricular arrhythmias in high-risk patients. JACC 2000; 36: 766-72.De Suttere J, Tavernier R, De Buyzere M, et al. Lipid-lowering drugs and recurrences of life-treating ventricular arrhythmias in high-risk patients. JACC 2000; 36: 766-72.Goldberger J, Subacius H, Schaechter A. Effects of statin therapy on arrhythmic events and survival in patients with nonischemic dilated cardiomyopathy. JACC 2006; 6: 1230-3.Goldberger J, Subacius H, Schaechter A. Effects of statin therapy on arrhythmic events and survival in patients with nonischemic dilated cardiomyopathy. JACC 2006; 6: 1230-3.Scandinavian Simvasthathin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary disease: the Scandinavian Simvasthatin Survival Study (4S). Lancet 1994; 344: 1349-57.Scandinavian Simvasthathin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary disease: the Scandinavian Simvasthatin Survival Study (4S). Lancet 1994; 344: 1349-57.Lipid Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol level. N Engl J Med 1998; 339: 1349-57.Lipid Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol level. N Engl J Med 1998; 339: 1349-57.Sever PS. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicenter randomized controlled trial. Lancet 2003; 361: 1149-58.Sever PS. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicenter randomized controlled trial. Lancet 2003; 361: 1149-58.Pedersen TR. High-dose atorvastatin vs usual dose simvastatin for secondary prevention after myocardial infarction. The IDEAL Study: a randomized controlled trial. JAMA 2005; 294: 2437-45.Pedersen TR. High-dose atorvastatin vs usual dose simvastatin for secondary prevention after myocardial infarction. The IDEAL Study: a randomized controlled trial. JAMA 2005; 294: 2437-45.Koren MJ, Hunningghake DB. Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics. The Alliance Study. JACC 2004; 44: 1722-9.Koren MJ, Hunningghake DB. Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics. The Alliance Study. JACC 2004; 44: 1722-9.Schwartz GG. Effect of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACLE Study: A randomised Controlled Trial. JAMA 2001; 285: 1711-8.Schwartz GG. Effect of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACLE Study: A randomised Controlled Trial. JAMA 2001; 285: 1711-8.Colhoun HM. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicente randomized placebo-controlled trial. Lancet 2004; 364: 685-96.Colhoun HM. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicente randomized placebo-controlled trial. Lancet 2004; 364: 685-96.Chung MK, Martin DO, Sprecher D, et al. C-reactive protein . in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation 2001; 104: 2886-91.Chung MK, Martin DO, Sprecher D, et al. C-reactive protein . in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation 2001; 104: 2886-91.Strandberg TE, Vanhanen H, Tikkonen MJ. Effect of statins on C-reactive protein in patients with coronary artery disease. Lancet 1999; 353: 118-9.Strandberg TE, Vanhanen H, Tikkonen MJ. Effect of statins on C-reactive protein in patients with coronary artery disease. Lancet 1999; 353: 118-9.Сусеков А., Рожкова Т., Зубарева М. Эффективность действия Aторвастатина на сосудистую стенку и СРБ. Кардиология 2006; 9: 4-9.Сусеков А., Рожкова Т., Зубарева М. Эффективность действия Aторвастатина на сосудистую стенку и СРБ. Кардиология 2006; 9: 4-9.Gensini F, Padeletti L, Fatini C, et al. Angiotensin-converting enzyme and endothelial nitric oxide synthase polymorphisms in patients with atrial fibrillation. Pacing Clin Electrophysiol 2003; 26: 295-8.Gensini F, Padeletti L, Fatini C, et al. Angiotensin-converting enzyme and endothelial nitric oxide synthase polymorphisms in patients with atrial fibrillation. Pacing Clin Electrophysiol 2003; 26: 295-8.Liu T, Li GP. Statins may prevent postoperative atrial fibrillation through autonomic modulation. Am J Cardiol 2006; 97: 1266.Liu T, Li GP. Statins may prevent postoperative atrial fibrillation through autonomic modulation. Am J Cardiol 2006; 97: 1266.Young-Xu Y, Jabbour S, Goldberg R, et al. Usefulness of statin drugs against atrial fibrillation in patients with coronary artery disease. Am J Cardiol 2003; 92(12): 1379-83.Young-Xu Y, Jabbour S, Goldberg R, et al. Usefulness of statin drugs against atrial fibrillation in patients with coronary artery disease. Am J Cardiol 2003; 92(12): 1379-83.Siu CW, Lau CP, Tse HF. Prevention of atrial fibrillation recurrence by statin therapy in patients with lone atrial fibrillation after successful cardioversion. Am J Cardiol 2003; 92(11): 1343-5.Siu CW, Lau CP, Tse HF. Prevention of atrial fibrillation recurrence by statin therapy in patients with lone atrial fibrillation after successful cardioversion. Am J Cardiol 2003; 92(11): 1343-5.Ozaydin M, Varol E, Aslan S, et al. Effect of Atorvastatin on the Recurrence Rates of Atrial Fibrillation After Electrical Cardioversion. Am J Cardiol 2006; 97: 1490-3.Ozaydin M, Varol E, Aslan S, et al. Effect of Atorvastatin on the Recurrence Rates of Atrial Fibrillation After Electrical Cardioversion. Am J Cardiol 2006; 97: 1490-3.Dernellis J, Panaretou M. Relationship between C-reactive protein reduction on paroxysmal atrial fibrillation. Am Heart J 2004; 150: 1064.Dernellis J, Panaretou M. Relationship between C-reactive protein reduction on paroxysmal atrial fibrillation. Am Heart J 2004; 150: 1064.Amar D, Zhang H, Heerdt PM, et al. Statin use is associated with a reduction in atrial fibrillation after noncardiac thoracic surgery independent of C-reactive protein. Chest 2005; 128: 3421-7.Amar D, Zhang H, Heerdt PM, et al. Statin use is associated with a reduction in atrial fibrillation after noncardiac thoracic surgery independent of C-reactive protein. Chest 2005; 128: 3421-7.Marin F, Pascual DA, Roldan V, et al. Statins and postoperative risk of atrail fibrillation following coronary artery bypass grafting. Am J Cardiol 2006; 97(1): 55-60.Marin F, Pascual DA, Roldan V, et al. Statins and postoperative risk of atrail fibrillation following coronary artery bypass grafting. Am J Cardiol 2006; 97(1): 55-60.Patel AA, White M, Shah S, et al. The relationship betwen statin use and atrial fibrillation. Curr Med Res and Opin 2007; 5: 1177-85.Patel AA, White M, Shah S, et al. The relationship betwen statin use and atrial fibrillation. Curr Med Res and Opin 2007; 5: 1177-85.

The authors declare that there are no conflicts of interest present.